# Surrozen (SRZN) — News

SRZN · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/srzn/news

## Recent headlines

- [Surrozen, - First patient dosing in duet study expected in Q4 2026](https://www.ainvest.com/news/surrozen-patient-dosing-duet-study-expected-q4-2026-2610) — AInvest Wire, Oct 2, 2026
- [Surrozen announces FDA clearance of IND application for SZN-8141 for the treatment of diabetic macular edema](https://www.ainvest.com/news/surrozen-announces-fda-clearance-ind-application-szn-8141-treatment-diabetic-macular-edema-2610) — AInvest Wire, Oct 2, 2026
- [Surrozen, - To initiate Duet phase 1B/2A study by year-end 2026, initial data in H2 2027](https://www.ainvest.com/news/surrozen-initiate-duet-phase-1b-2a-study-year-2026-initial-data-h2-2027-2609) — AInvest Wire, Sep 8, 2026
- [Surrozen submits ind application for SZN-8141 in DME](https://www.ainvest.com/news/surrozen-submits-ind-application-szn-8141-dme-2609) — AInvest Wire, Sep 8, 2026
- [Surrozen announces submission of ind application for SZN-8141 for the treatment of diabetic macular edema](https://www.ainvest.com/news/surrozen-announces-submission-ind-application-szn-8141-treatment-diabetic-macular-edema-2609) — AInvest Wire, Sep 8, 2026
  Surrozen, Inc. (Nasdaq: SRZN) announced plans to submit an Investigational New Drug (IND) application for its product candidate SZN-8141 for the treatment of diabetic macular edema (DME) by end of third quarter 2026 . This development is part of the company’s ongoing efforts to advance its…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).